- Stocks
- Healthcare
- NYSEAMERICAN: LCTX

Price (delayed)

$2.7

Market cap

$437.78M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.09

Enterprise value

$384.6M

LCTX's EPS has soared by 78% year-on-year and by 36% since the previous quarter

The company's net income has surged by 77% YoY and by 34% QoQ

The gross profit has plunged by 51% YoY and by 10% from the previous quarter

The revenue has contracted by 45% YoY and by 7% from the previous quarter

What are the main financial stats of LCTX

Market
Valuations
Earnings

Shares outstanding

162.14M

Market cap

$437.78M

Enterprise value

$384.6M

Price to earnings (P/E)

N/A

Price to book (P/B)

3.71

Price to sales (P/S)

251.65

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

225.84

Revenue

$1.7M

EBIT

-$14.91M

EBITDA

-$13.22M

Free cash flow

-$22.19M

Per share
Balance sheet
Liquidity

EPS

-$0.09

Free cash flow per share

-$0.14

Book value per share

$0.73

Revenue per share

$0.01

TBVPS

$0.44

Total assets

$127.93M

Total liabilities

$11.36M

Debt

$3.03M

Equity

$117.67M

Working capital

$58M

Debt to equity

0.03

Current ratio

9.76

Quick ratio

9.44

Net debt/EBITDA

4.02

Margins
Efficiency
Dividend

EBITDA margin

-776.1%

Gross margin

76.3%

Net margin

-802.5%

Operating margin

-1,530.2%

Return on assets

-12.1%

Return on equity

-13.5%

Return on invested capital

-86%

Return on capital employed

-12.3%

Return on sales

-875.2%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the Lineage Cell Therapeutics stock price performed over time

Intraday

-4.93%

1 week

-5.92%

1 month

17.9%

1 year

162.14%

YTD

53.41%

QTD

14.89%

How have Lineage Cell Therapeutics's revenue and profit performed over time

Revenue

$1.7M

Gross profit

$1.3M

Operating income

-$26.06M

Net income

-$13.67M

Gross margin

76.3%

Net margin

-802.5%

The company's net income has surged by 77% YoY and by 34% QoQ

The net margin has soared by 58% YoY and by 29% from the previous quarter

The gross profit has plunged by 51% YoY and by 10% from the previous quarter

The revenue has contracted by 45% YoY and by 7% from the previous quarter

What is Lineage Cell Therapeutics's growth rate over time

What is Lineage Cell Therapeutics stock price valuation

P/E

N/A

P/B

3.71

P/S

251.65

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

225.84

LCTX's EPS has soared by 78% year-on-year and by 36% since the previous quarter

LCTX's P/B is 86% above its 5-year quarterly average of 2.0 and 69% above its last 4 quarters average of 2.2

LCTX's equity is up by 22% QoQ and by 10% YoY

LCTX's price to sales (P/S) is 117% more than its last 4 quarters average of 115.9

The revenue has contracted by 45% YoY and by 7% from the previous quarter

How efficient is Lineage Cell Therapeutics business performance

LCTX's return on equity has surged by 73% year-on-year and by 36% since the previous quarter

Lineage Cell Therapeutics's ROA has soared by 73% YoY and by 35% from the previous quarter

LCTX's ROS has soared by 57% year-on-year and by 27% since the previous quarter

Lineage Cell Therapeutics's ROIC has increased by 18% YoY but it has decreased by 5% from the previous quarter

What is LCTX's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for LCTX.

How did Lineage Cell Therapeutics financials performed over time

Lineage Cell Therapeutics's quick ratio has surged by 76% QoQ and by 31% YoY

The current ratio has surged by 72% since the previous quarter and by 30% year-on-year

The debt is 97% less than the equity

The debt to equity has contracted by 40% YoY

The debt has contracted by 37% YoY and by 8% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.